CD200R1-Protein

Migration, Crosslink

📖

CD200R1-Protein

active

wiki page Created: 2026-04-02T07:19:09 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-cd200r1-protein

📖 Wiki Page

protein1810 wordssynced 2026-04-02

CD200R1 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">CD200R1-Protein</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">MAPK/ERK</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">NF-κB</td>
<td>Suppression</td>
</tr>
<tr>
<td class="label">STAT1</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>Modulation</td>
</tr>
<tr>
<td class="label">NLRP3 inflammasome</td>
<td>Suppression</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">CD200R1 agonists</td>
<td>Direct receptor activation</td>
</tr>
<tr>
<td class="label">CD200-Fc</td>
<td>Enhanced CD200 engagement</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-CD200R1</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Type</td>
</tr>
<tr>
<td class="label">CD200-Fc</td>
<td>Fusion protein</td>
</tr>
<tr>
<td class="label">Anti-CD200R1 mAb</td>
<td>Monoclonal antibody</td>
</tr>
<tr>
<td class="label">CD200R1 mimetic peptides</td>
<td>Small molecules</td>
</tr>
<tr>
<td class="label">Recombinant CD200</td>
<td>Ligand-based</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/parkinson" style="color:#ef9a9a">Parkinson</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">3 edges</a></t

...

CD200R1 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">CD200R1-Protein</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">MAPK/ERK</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">NF-κB</td>
<td>Suppression</td>
</tr>
<tr>
<td class="label">STAT1</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>Modulation</td>
</tr>
<tr>
<td class="label">NLRP3 inflammasome</td>
<td>Suppression</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">CD200R1 agonists</td>
<td>Direct receptor activation</td>
</tr>
<tr>
<td class="label">CD200-Fc</td>
<td>Enhanced CD200 engagement</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-CD200R1</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Type</td>
</tr>
<tr>
<td class="label">CD200-Fc</td>
<td>Fusion protein</td>
</tr>
<tr>
<td class="label">Anti-CD200R1 mAb</td>
<td>Monoclonal antibody</td>
</tr>
<tr>
<td class="label">CD200R1 mimetic peptides</td>
<td>Small molecules</td>
</tr>
<tr>
<td class="label">Recombinant CD200</td>
<td>Ligand-based</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/parkinson" style="color:#ef9a9a">Parkinson</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">3 edges</a></td>
</tr>
</table>

Introduction

CD200 Receptor 1 (CD200R1) is a critical inhibitory immune receptor expressed primarily on microglia and other myeloid cells in the central nervous system. As the receptor for the CD200 (OX-2) glycoprotein, CD200R1 transduces powerful immunosuppressive signals that maintain microglial quiescence and prevent excessive neuroinflammation. This receptor represents a key component of the brain's endogenous immune checkpoint system.

The CD200-CD200R1 axis is one of the most important endogenous mechanisms for maintaining immunological quiescence in the CNS. Dysregulation of this pathway has been strongly implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), stroke, and other neurodegenerative conditions. The therapeutic potential of CD200R1 agonism has made it an attractive target for drug development aimed at modulating neuroinflammation.

This comprehensive review examines the structure and biochemistry of CD200R1, its normal physiological functions in the CNS, the mechanisms by which its dysfunction contributes to neurodegenerative diseases, and current therapeutic strategies targeting this important immune regulatory pathway. [@heneka2015]

Structure

Primary Structure and Domain Architecture

CD200R1 is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily. The protein consists of:

Extracellular domain: Approximately 262 amino acids containing two immunoglobulin-like domains (one V-set and one C2-set domain)
Transmembrane region: 21 amino acids with a conserved cysteine for potential palmitoylation
Cytoplasmic tail: 220-270 amino acids containing critical signaling motifs

The extracellular region of CD200R1 shares structural features with other immune-inhibitory receptors, but has distinct binding characteristics specific for CD200. The V-set immunoglobulin domain at the N-terminus contains the CD200 binding interface.

Immunoreceptor Tyrosine-Based Inhibitory Motifs (ITIMs)

The cytoplasmic tail of CD200R1 contains multiple ITIMs that mediate its inhibitory function:

ITIM 1: YXXL/V sequence at position 294-297
ITIM 2: YXXL/V sequence at position 331-334
ITIM 3: YXXL/V sequence at position 418-421

These ITIMs recruit protein tyrosine phosphatases (SHP-1 and SHP-2) upon receptor activation, leading to downstream signal inhibition.

Post-Translational Modifications

CD200R1 undergoes several post-translational modifications:

N-linked glycosylation: Multiple N-glycosylation sites in the extracellular domain
Palmitoylation: At cysteine residues near the transmembrane domain for membrane localization
Phosphorylation: Tyrosine residues in ITIMs are phosphorylated upon ligand binding

Structural Basis for Ligand Recognition

The CD200R1 extracellular domain adopts a characteristic immunoglobulin fold:

V-set domain: N-terminal domain with complementarity-determining regions (CDRs) for CD200 binding
C2-set domain: Membrane-proximal domain providing structural support
Linker region: Flexible hinge connecting the two Ig domains

Structural studies have revealed the CD200-CD200R1 interaction interface in detail, showing that a single CD200 molecule can engage two CD200R1 molecules, facilitating receptor clustering and signal transduction. [@wright2010]

Normal Function

CD200R1 Signaling Mechanisms

CD200R1 transduces inhibitory signals through a well-characterized cascade:

Ligand binding: CD200 engagement induces CD200R1 oligomerization

ITIM phosphorylation: Src family kinases phosphorylate tyrosine residues within ITIMs

Phosphatase recruitment: SHP-1 and SHP-2 bind to phosphorylated ITIMs through their SH2 domains

Signal dephosphorylation: Phosphatases dephosphorylate key signaling molecules

Inflammatory suppression: Reduced activation of MAPK, NF-κB, and other pro-inflammatory pathways

Functions in the CNS

CD200R1 signaling is essential for maintaining CNS homeostasis:

Microglial Surveillance State: CD200R1 signaling maintains microglia in a ramified surveillance phenotype, preventing unnecessary activation [@ransohoff2016]

Inflammatory Response Limiting: The pathway suppresses pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6)

Phagocytosis Regulation: Modulates microglial phagocytic activity to prevent excessive debris clearance

Synaptic Pruning Modulation: Regulates complement-mediated synaptic elimination [@song2018]

Neuroprotection: Provides inherent protection against neuroinflammatory insults

Cellular Expression Patterns

CD200R1 Expression (cell types with highest expression):

Microglia (highest expression in the CNS)
Perivascular macrophages
Some subsets of peripheral macrophages
Certain dendritic cell populations
Low expression on some T cell subsets

Expression Changes in Disease:

CD200R1 expression is downregulated on microglia in AD and PD
Reduced receptor levels correlate with disease severity
Age-related decline in CD200R1 contributes to increased neuroinflammation

Signaling Pathways Regulated by CD200R1

CD200R1 signaling modulates multiple downstream pathways:

Role in Neurodegenerative Diseases

Alzheimer's Disease

CD200R1 Dysregulation in AD

Multiple studies have documented significant alterations in the CD200-CD200R1 pathway in Alzheimer's disease:

Reduced CD200R1 expression: 40-60% decrease in AD brain tissue
Impaired ITIM signaling: Reduced phosphatase recruitment and signaling
Correlation with pathology: Changes correlate with amyloid burden, tau pathology, and cognitive decline
Microglial phenotype shift: Loss of CD200R1 contributes to inflammatory microglial phenotype [@keren-shaul2017]

Mechanisms of CD200R1 Dysfunction in AD

Amyloid-β Effects: Aβ oligomers contribute to CD200R1 dysfunction through:

Direct interference with CD200-CD200R1 interaction
Induction of CD200R1 internalization and degradation
Competitive binding to CD200R1
Disruption of receptor clustering required for optimal signaling

Tau Pathology Impact: Hyperphosphorylated tau is associated with further reduction in CD200R1 expression, creating synergistic immune dysregulation. [@hu2022]

Neuroinflammation Feedback Loop: Chronic neuroinflammation leads to:

Epigenetic silencing of CD200R1 gene expression
Reduced transcription of CD200R1 mRNA
Increased receptor degradation

Therapeutic Implications for AD

Strategies targeting CD200R1 in AD include:

CD200R1 Agonists: Recombinant proteins or antibodies that activate CD200R1

Small Molecule Enhancers: Compounds that potentiate CD200R1 signaling

Gene Therapy: AAV-mediated CD200R1 overexpression

Phosphatase Modulators: Enhancing SHP-1/SHP-2 recruitment

Preclinical studies have shown that CD200R1 agonists can:

Reduce amyloid-induced neuroinflammation
Improve cognitive function in AD models
Modulate microglial phagocytosis of Aβ
Protect against synaptic loss [@yang2021]

Parkinson's Disease

CD200R1 in PD Pathogenesis

In Parkinson's disease, CD200R1 dysregulation contributes to neuroinflammation in affected brain regions:

Reduced CD200R1: Decreased expression on microglia in substantia nigra
Enhanced microglial activation: Loss of inhibitory signaling correlates with dopaminergic neuron loss
α-Synuclein interactions: α-Synuclein oligomers may interfere with CD200R1 signaling

Evidence from Models

CD200R1 knockout mice show enhanced vulnerability to MPTP-induced parkinsonism
CD200R1 agonists protect against 6-OHDA toxicity
CD200R1 deficiency leads to increased inflammatory responses in PD models [@liu2019]

Therapeutic Targeting in PD

Multiple Sclerosis

CD200R1 in MS

In multiple sclerosis and experimental autoimmune encephalomyelitis (EAE):

CD200R1 expression is reduced on microglia in demyelinating lesions
Loss of CD200R1 signaling contributes to inflammatory demyelination
Restoration of CD200-CD200R1 signaling ameliorates EAE [@wu2023]

Mechanisms

The CD200R1 pathway limits:

T cell activation and infiltration
Pro-inflammatory cytokine production by microglia
Demyelination and axonal loss
Microglial proliferation and activation

Amyotrophic Lateral Sclerosis (ALS)

CD200R1 alterations in ALS:

Reduced CD200R1 expression in motor cortex and spinal cord
Correlation with disease progression
CD200R1 microglial expression changes with disease stage [@li2021]

Stroke and Ischemic Injury

CD200R1 plays protective roles after stroke:

CD200R1 signaling limits post-ischemic inflammation
CD200R1 agonists reduce infarct size in models
The pathway promotes neurological recovery [@wang2019]

Vascular Dementia

CD200R1 dysfunction contributes to vascular cognitive impairment:

Cerebrovascular disease affects CD200R1 expression
Cognitive decline correlates with receptor dysfunction
Therapeutic targeting shows promise [@liu2023]

Signaling Pathways and Mechanisms

CD200R1 Signaling Cascade

CD200R1 signaling involves multiple downstream pathways:

SHP-1/SHP-2 Recruitment: Primary inhibitory signaling through ITIMs

MAPK Inhibition: Reduced ERK activation in response to inflammatory stimuli

NF-κB Suppression: Decreased p65 nuclear translocation

STAT1 Inhibition: Reduced interferon-responsive gene expression

NLRP3 Inflammasome Suppression: Reduced caspase-1 activation and IL-1β production

Cross-talk with Other Immune Pathways

CD200R1 signaling intersects with multiple neuroimmune pathways:

TLR Signaling: CD200R1 can suppress TLR-induced inflammation
CX3CR1 Pathway: Synergistic with fractalkine signaling
TREM2 Pathways: Coordinate microglial regulatory mechanisms
Complement System: Modulates complement-mediated phagocytosis

Cell-Type Specific Effects

CD200R1 signaling has distinct effects on different cell types:

Microglia: Maintains surveillance state, limits cytokine production, modulates phagocytosis
Macrophages: Reduces phagocytic activity and antigen presentation
Perivascular macrophages: Limits CNS immune entry

Therapeutic Targeting

Agonist Approaches

Gene Therapy Approaches

AAV-CD200R1: Adeno-associated virus-mediated gene delivery
Lentiviral vectors: Ex vivo modification of cells
Gene editing: CRISPR-based approaches to enhance CD200R1 expression

Combination Strategies

CD200R1 agonist + CSF1R inhibitor: Combined immune modulation
CD200R1 agonist + anti-inflammatory drugs: Synergistic effects
CD200R1 agonist + neurotrophic factors: Immune modulation + neuroprotection

Biomarkers and Patient Selection

Potential biomarkers for CD200R1-targeted therapy:

CD200R1 expression levels on peripheral monocytes
CSF soluble CD200R1 levels
Genetic polymorphisms in CD200R1 gene

Genetic Variations

The CD200R1 gene contains several polymorphisms that may influence disease risk:

Promoter variants: Affect CD200R1 expression levels
Coding variants: May alter receptor function
3'UTR variants: Affect mRNA stability

These variations may contribute to inter-individual differences in disease progression and treatment response. [@chen2021]

[CD200 Gene](/genes/cd200)
[CD200 Protein](/proteins/CD200-Protein)
[Neuroinflammation](/mechanisms/neuroinflammation)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Microglia](/cell-types/microglia)
[CX3CR1 Signaling](/mechanisms/cx3cr1-pathway)
[TREM2 Signaling](/mechanisms/trem2-signaling-pathway)
[CSF1R Signaling](/mechanisms/csf1r-pathway)
[Neuroinflammation Pathway](/mechanisms/neuroinflammation)

Key Publications

[The CD200-CD200R pathway in immune regulation](https://pubmed.ncbi.nlm.nih.gov/12072352/). Trends in Immunology. 2002.

[Neuroinflammation in Alzheimer's disease and Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/25646422/). Lancet Neurology. 2015.

[A unique microglia type associated with restricting development of Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/28515449/). Cell. 2017.

[The identity and function of microglia in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/30026556/). Nature Immunology. 2018.

[CD200R1 signaling in Parkinson's disease models](https://pubmed.ncbi.nlm.nih.gov/30694242/). Molecular Neurobiology. 2019.

[CD200R1 agonist attenuates cerebral ischemia/reperfusion injury](https://pubmed.ncbi.nlm.nih.gov/31181262/). Brain Research. 2019.

[CD200R1 and neuroinflammation: From basic science to therapeutic applications](https://pubmed.ncbi.nlm.nih.gov/32061847/). Pharmacological Research. 2020.

[CD200R1 agonist restores cognitive function in Alzheimer's models](https://pubmed.ncbi.nlm.nih.gov/34048932/). Neurobiology of Aging. 2021.

[CD200R1 signaling regulates microglial phagocytosis in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/35642187/). J Neuroinflammation. 2022.

[Single-cell analysis of CD200R1 expression in aging brain](https://pubmed.ncbi.nlm.nih.gov/36038654/). Nature Aging. 2022.

[CD200R1 deficiency exacerbates tau pathology](https://pubmed.ncbi.nlm.nih.gov/36309734/). Acta Neuropathol Commun. 2022.

[CD200R1 agonists in Parkinson's disease: preclinical validation](https://pubmed.ncbi.nlm.nih.gov/36951128/). Movement Disorders. 2023.

[CD200R1 and neuroinflammation in multiple sclerosis](https://pubmed.ncbi.nlm.nih.gov/37154123/). Mult Scler. 2023.

External Links

[UniProt: Q9Y6W5](https://www.uniprot.org/uniprot/Q9Y6W5)
[PDB: 2OUB](https://www.rcsb.org/structure/2OUB)
[PDB: 4N5G](https://www.rcsb.org/structure/4N5G)
[AlphaFold: CD200R1](https://alphafold.ebi.ac.uk/entry/Q9Y6W5)
[GeneCards: CD200R1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD200R1)
[IUPHAR: CD200R](https://www.guidetopharmacology.org/GTP/RCDb.html)

Brain Atlas Resources

[Allen Human Brain Atlas](https://human.brain-map.org/) — protein expression data
[Allen Cell Type Atlas](https://celltypes.brain-map.org/) — cell type specific expression
[BrainSpan Atlas](https://brainspan.org/) — developmental transcriptome
[Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — mouse brain expression

📖 View canonical wiki page →

Related Entities

CD200R1PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-cd200r1-protein
kg_node_id	CD200R1PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0a17ba72fc84
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-cd200r1-protein'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

18

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CD200R1-Protein

CD200R1 Protein

CD200R1 Protein

Introduction

Structure

Primary Structure and Domain Architecture

Immunoreceptor Tyrosine-Based Inhibitory Motifs (ITIMs)

Post-Translational Modifications

Structural Basis for Ligand Recognition

Normal Function

CD200R1 Signaling Mechanisms

Functions in the CNS

Cellular Expression Patterns

Signaling Pathways Regulated by CD200R1

Role in Neurodegenerative Diseases

Alzheimer's Disease

CD200R1 Dysregulation in AD

Mechanisms of CD200R1 Dysfunction in AD

Therapeutic Implications for AD

Parkinson's Disease

CD200R1 in PD Pathogenesis

Evidence from Models

Therapeutic Targeting in PD

Multiple Sclerosis

CD200R1 in MS

Mechanisms

Amyotrophic Lateral Sclerosis (ALS)

Stroke and Ischemic Injury

Vascular Dementia

Signaling Pathways and Mechanisms

CD200R1 Signaling Cascade

Cross-talk with Other Immune Pathways

Cell-Type Specific Effects

Therapeutic Targeting

Agonist Approaches

Gene Therapy Approaches

Combination Strategies

Biomarkers and Patient Selection

Genetic Variations

Cross-Links to Related Topics

Key Publications

See Also

External Links

Brain Atlas Resources

💬 Discussion